Research Summary

My research program has been highly focused on identifying and overriding molecular mechanisms of resistance to targeted therapeutics in hematopoietic malignancies, and is highly translational in nature. I therefore rely heavily upon HDFCCC infrastructure, including the Phase I Unit in the Developmental Therapeutics Program, the Tissue Core, the Bioinformatics Core, and the Mouse Therapeutics Core Facility. Additionally, I have ongoing Intra- and Inter-Programmatic collaborations with numerous Members and Associate Members, including Benjamin Braun, Emmanuelle Passegue, Scott Kogan, Mignon Loh, and Kevan Shokat.

Research Funding

  • August 1, 2015 - July 31, 2019 - Discovery and Development of a Selective pan-FLT3-ITD Kinase Inhibitor Clinical Candidate for the Treatment of FLT3-ITD-Driven AML , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA194094
  • April 8, 2013 - March 31, 2018 - Crenolanib and ponatinib for the treatment of FLT3 mutant AML , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA176091
  • April 17, 2012 - March 31, 2017 - Mechanisms of resistance to clinically-effective FLT3 kinase inhibitors in AML , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA166616
  • September 23, 2015 - August 31, 2016 - Pre-IND study of PMT-254, a pan-FLT3 inhibitor for the treatment of FLT3 driven cancers. , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R41CA199753
  • March 1, 1982 - May 31, 2015 - Bio-Organic Biomedical Mass Spectrometry Resource , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P41RR001614

Education

University of California, Berkeley, BS,1984, Genetics
University of California, Los Angeles, PhD, 1992, Microbiology & Molecular Genetics
University of California, Los Angeles, MD, 1996, Medicine

Honors & Awards

  • 1989-1991
    National Institutes of Health Predoctoral Award in Tumor Cell Biology
  • 1995
    Alpha Omega Alpha Medical Student Research Prize
  • 1995-2003
    UCLA Specialty Training and Advanced Research (STAR) Award
  • 2001-2004
    Leukemia and Lymphoma Society Career Development Award for Fellows
  • 2003-2005
    NIH K12 Award in Clinical Pharmacology
  • 2004-2007
    Leukemia and Lymphoma Society Career Development Award for Special Fellows
  • 2006-2009
    Doris Duke Charitable Foundation Clinical Scientist Development Award
  • 2009-2014
    Leukemia and Lymphoma Society Scholar in Clinical Research Award
  • 2024
    2024 Rowley Prize for exceptional lifetime achievements in advancing the understanding of the biology of CML 

Selected Publications

  1. Sandler T, Manglicmot S, Mullen KM, Shah N, Philip J Pragmatic Use of Minimal Common Oncology Data Elements and Observational Medical Outcomes Partnership at an Academic Medical Center.  View on PubMed
  2. Zhang Y, Lev-Ari S, Zaemes J, Della Pia A, DeAgresta B, Gupta S, Marki A, Zemel R, Ip A, Alaoui A, Charalampous C, Rahman I, Wilkins O, Madhavan S, McGarvey P, Pascual L, Atkins MB, Shah NJ Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions.  View on PubMed
  3. Siev A, Livingstone P, Tom E, Corso T, Preeshagul I, Postow M, Shah NJ, Niec R, Schattner M, Faleck DM Office-based flexible sigmoidoscopy allows rapid assessment and management of suspected immune checkpoint inhibitor-related colitis.  View on PubMed
  4. Beckermann KE, Shah NJ, Campbell MT, Haas NB, Nelson A, Ornstein MC, Mao S, Keshava-Prasad HS, Hammers H, Gao X, Gourdin T, George S, Hoimes CJ, Hussain A, Jonasch E, Rini BI, Voss MH Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.  View on PubMed
  5. Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. FOXA2 promotes metastatic competence in small cell lung cancer. Nat Commun. 2025 May 26; 16(1):4865.  View on PubMed
  6. Shah NJ, Sura S, Shinde R, Shi J, Bupathi M, Vickery D, Perini R, Motzer RJ. Real-World Treatment Patterns and Clinical Outcomes Among Patients with Metastatic Renal Cell Carcinoma Post-Immune-Oncology and Vascular Endothelial Growth Factor Receptor Targeted Therapies. Cancers (Basel). 2025 Apr 25; 17(9).  View on PubMed
  7. Leyte-Vidal AM, Shah NP. How I individualize treatment for chronic-phase CML. Blood. 2025 Apr 16.  View on PubMed
  8. Kotecha RR, Doshi SD, Knezevic A, Jacobi R, Woo HJ, Aggen DH, McHugh DJ, Shah NJ, Carlo MI, Keegan NM, Gayadin Y, Chaim J, Donoghue MTA, Iyer G, Lee CH, Feldman DR, Motzer RJ, Voss MH. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. Eur Urol Oncol. 2025 Mar 29.  View on PubMed
  9. Makker S, Shah NJ, Carlo MI, Kuo F, Hakimi AA, Chen YB, Iyer G, Kotecha RR Immune Checkpoint Blockade Response in Mucinous Tubular and Spindle Cell Carcinoma.  View on PubMed
  10. Shang J, Del Valle DM, Britton GJ, Mead KR, Rajpal U, Chen-Liaw A, Mogno I, Li Z, Menon R, Gonzalez-Kozlova E, Elkrief A, Peled JU, Gonsalves TR, Shah NJ, Postow M, Colombel JF, Gnjatic S, Faleck DM, Faith JJ. Baseline colitogenicity and acute perturbations of gut microbiota in immunotherapy-related colitis. J Exp Med. 2025 Jan 06; 222(1).  View on PubMed
  11. Carucci L, Shah N, Berni Canani R Editorial: New insights in pediatric gastrointestinal food allergies.  View on PubMed
  12. Sewell M, Toumbacaris N, Tan KS, Bahadur N, Philip J, Shah NJ, Niederhausern A, Tavarez Martinez C, Zheng H, Boerner T, Janjigian YY, Maron SB, Bott MJ, Gray KD, Park BJ, Sihag S, Jones DR, Ku GY, Wu AJ, Molena D. Esophagectomy may have a role in stage IV esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2024 Nov 22.  View on PubMed
  13. Shah NP. The promise of allosteric kinase inhibition. Blood. 2024 Nov 07; 144(19):1975-1976.  View on PubMed
  14. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]. Eur Urol. 2025 Jan; 87(1):96.  View on PubMed
  15. Leyte-Vidal A, Garrido Ruiz D, DeFilippis R, Leske IB, Rea D, Phan S, Miller KB, Hu F, Mase A, Shan Y, Hantschel O, Jacobson MP, Shah NP. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib. Blood. 2024 08 08; 144(6):639-645.  View on PubMed
  16. Leyte-Vidal A, DeFilippis R, Outhwaite IR, Kwan I, Lee JY, Leavitt C, Miller KB, Rea D, Rangwala AM, Lou K, Patel S, Alvarez A, Shokat KM, Bahar I, Seeliger MA, Shah NP. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib. Leukemia. 2024 Sep; 38(9):2046-2050.  View on PubMed
  17. Shah NJ, Shinde R, Moore KJ, Sainski-Nguyen A, Le LB, Cao F, Song R, Singhal P, Motzer RJ. Health Care Resource Use for Modern First-Line Treatments in Metastatic Renal Cell Carcinoma. JAMA Netw Open. 2024 07 01; 7(7):e2422674.  View on PubMed
  18. Lacouture ME, Goleva E, Shah N, Rotemberg V, Kraehenbuehl L, Ketosugbo KF, Merghoub T, Maier T, Bang A, Gu S, Salvador T, Moy AP, Lyubchenko T, Xiao O, Hall CF, Berdyshev E, Crooks J, Weight R, Kern JA, Leung DYM. Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways. Clin Cancer Res. 2024 Jul 01; 30(13):2822-2834.  View on PubMed
  19. Shah NJ, Della Pia A, Wu T, Williams A, Weber M, Sinclaire B, Gourna Paleoudis E, Alaoui A, Lev-Ari S, Adams S, Kaufman J, Parikh SB, Tonti E, Muller E, Serzan M, Cheruku D, Lee A, Sridhar A, Hee BTP, Ahn J, Pecora A, Ip A, Atkins MB. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials. Cancers (Basel). 2024 Jun 14; 16(12).  View on PubMed
  20. Wang X, DeFilippis RA, Yan W, Shah NP, Li HY. Overcoming Secondary Mutations of Type II Kinase Inhibitors. J Med Chem. 2024 Jun 27; 67(12):9776-9788.  View on PubMed

Go to UCSF Profiles, powered by CTSI